Active flexible concentric ring electrode for non-invasive surface bioelectrical recordings

Bioelectrical surface recordings are usually performed by unipolar or bipolar disc electrodes even though they entail the serious disadvantage of having poor spatial resolution. Concentric ring electrodes give improved spatial resolution, although this type of electrode has so far only been implemented in rigid substrates and as they are not adapted to the curvature of the recording surface may provide discomfort to the patient. Moreover, the signals recorded by these electrodes are usually lower in amplitude than conventional disc electrodes. The aim of this work was thus to develop and test a new modular active sensor made up of concentric ring electrodes printed on a flexible substrate by thick-film technology together with a reusable battery-powered signal-conditioning circuit. Simultaneous ECG recording with both flexible and rigid concentric ring electrodes was carried out on ten healthy volunteers at rest and in motion. The results show that flexible concentric ring electrodes not only present lower skin electrode contact impedance and lower baseline wander than rigid electrodes but are also less sensitive to interference and motion artefacts. We believe these electrodes, which allow bioelectric signals to be acquired non-invasively with better spatial resolution than conventional disc electrodes, to be a step forward in the development of new monitoring systems based on Laplacian potential recordings.This research was supported in part by the Ministerio de Ciencia y Tecnologia de Espana (TEC2010-16945) and by the Universitat Politecnica de Valencia (PAID 2009/10-2298). The proof-reading of this paper was funded by the Universitat Politecnica de Valencia, Spain.Prats Boluda, G.; Ye Lin, Y.; García Breijo, E.; Ibáñez Civera, FJ.; Garcia Casado, FJ. (2012). Active flexible concentric ring electrode for non-invasive surface bioelectrical recordings. Measurement Science and Technology. 23(12):1-10. https://doi.org/10.1088/0957-0233/23/12/125703S1102312Malmivuo, J., & Plonsey, R. (1995). BioelectromagnetismPrinciples and Applications of Bioelectric and Biomagnetic Fields. doi:10.1093/acprof:oso/9780195058239.001.0001Gevins, A. (1989). Dynamic functional topography of cognitive tasks. Brain Topography, 2(1-2), 37-56. doi:10.1007/bf01128842Bradshaw, L. A., Wijesinghe, R. S., & Wikswo, Jr., J. P. (2001). Spatial Filter Approach for Comparison of the Forward and Inverse Problems of Electroencephalography and Magnetoencephalography. Annals of Biomedical Engineering, 29(3), 214-226. doi:10.1114/1.1352641Bradshaw, L. A., Richards, W. O., & Wikswo, J. P. (2001). Volume conductor effects on the spatial resolution of magnetic fields and electric potentials from gastrointestinal electrical activity. Medical & Biological Engineering & Computing, 39(1), 35-43. doi:10.1007/bf02345264Garcia-Casado, J., Martinez-de-Juan, J. L., & Ponce, J. L. (2005). Noninvasive Measurement and Analysis of Intestinal Myoelectrical Activity Using Surface Electrodes. IEEE Transactions on Biomedical Engineering, 52(6), 983-991. doi:10.1109/tbme.2005.846730SippensGroenewegen, A., Peeters, H. A. P., Jessurun, E. R., Linnenbank, A. C., Robles de Medina, E. O., Lesh, M. D., & van Hemel, N. M. (1998). Body Surface Mapping During Pacing at Multiple Sites in the Human Atrium. Circulation, 97(4), 369-380. doi:10.1161/01.cir.97.4.369Lian, J., Li, G., Cheng, J., Avitall, B., & He, B. (2002). Body surface Laplacian mapping of atrial depolarization in healthy human subjects. Medical & Biological Engineering & Computing, 40(6), 650-659. doi:10.1007/bf02345304Wu, D., Tsai, H. C., & He, B. (1999). On the Estimation of the Laplacian Electrocardiogram during Ventricular Activation. Annals of Biomedical Engineering, 27(6), 731-745. doi:10.1114/1.224Koka, K., & Besio, W. G. (2007). Improvement of spatial selectivity and decrease of mutual information of tri-polar concentric ring electrodes. Journal of Neuroscience Methods, 165(2), 216-222. doi:10.1016/j.jneumeth.2007.06.007Prats-Boluda, G., Garcia-Casado, J., Martinez-de-Juan, J. L., & Ye-Lin, Y. (2011). Active concentric ring electrode for non-invasive detection of intestinal myoelectric signals. Medical Engineering & Physics, 33(4), 446-455. doi:10.1016/j.medengphy.2010.11.009He, B., & Cohen, R. J. (1992). Body surface Laplacian mapping of cardiac electrical activity. The American Journal of Cardiology, 70(20), 1617-1620. doi:10.1016/0002-9149(92)90471-aBesio, W., Aakula, R., Koka, K., & Dai, W. (2006). Development of a Tri-polar Concentric Ring Electrode for Acquiring Accurate Laplacian Body Surface Potentials. Annals of Biomedical Engineering, 34(3), 426-435. doi:10.1007/s10439-005-9054-8Ye-Lin, Y., Garcia-Casado, J., Prats-Boluda, G., Ponce, J. L., & Martinez-de-Juan, J. L. (2009). Enhancement of the non-invasive electroenterogram to identify intestinal pacemaker activity. Physiological Measurement, 30(9), 885-902. doi:10.1088/0967-3334/30/9/002Hjorth, B. (1975). An on-line transformation of EEG scalp potentials into orthogonal source derivations. Electroencephalography and Clinical Neurophysiology, 39(5), 526-530. doi:10.1016/0013-4694(75)90056-5Perrin, F., Pernier, J., Bertnard, O., Giard, M. ., & Echallier, J. . (1987). Mapping of scalp potentials by surface spline interpolation. Electroencephalography and Clinical Neurophysiology, 66(1), 75-81. doi:10.1016/0013-4694(87)90141-6Nunez, P. L., & Westdorp, A. F. (1994). The surface laplacian, high resolution EEG and controversies. Brain Topography, 6(3), 221-226. doi:10.1007/bf01187712Srinivasan, R., Nunez, P. L., Tucker, D. M., Silberstein, R. B., & Cadusch, P. J. (1996). Spatial sampling and filtering of EEG with spline Laplacians to estimate cortical potentials. Brain Topography, 8(4), 355-366. doi:10.1007/bf01186911Farina, D., & Cescon, C. (2001). Concentric-ring electrode systems for noninvasive detection of single motor unit activity. IEEE Transactions on Biomedical Engineering, 48(11), 1326-1334. doi:10.1109/10.959328G. Besio, C. C. Lu, P. P. Tarjan, W. (2001). A Feasibility Study for Body Surface Cardiac Propagation Maps of Humans from Laplacian Moments of Activation. Electromagnetics, 21(7-8), 621-632. doi:10.1080/027263401752246243Li, G., Wang, Y., Lin, L., Jiang, W., Wang, L. L., Lu, S. C.-Y., & Besio, W. G. (2005). Active Laplacian electrode for the data-acquisition system of EHG. Journal of Physics: Conference Series, 13, 330-335. doi:10.1088/1742-6596/13/1/077Engel, J., Chen, J., & Liu, C. (2003). Development of polyimide flexible tactile sensor skin. Journal of Micromechanics and Microengineering, 13(3), 359-366. doi:10.1088/0960-1317/13/3/302Papakostas, T. V., Lima, J., & Lowe, M. (s. f.). A large area force sensor for smart skin applications. Proceedings of IEEE Sensors. doi:10.1109/icsens.2002.1037366Stieglitz, T. (2001). Flexible biomedical microdevices with double-sided electrode arrangements for neural applications. Sensors and Actuators A: Physical, 90(3), 203-211. doi:10.1016/s0924-4247(01)00520-9Hamilton, P. S., & Tompkins, W. J. (1986). Quantitative Investigation of QRS Detection Rules Using the MIT/BIH Arrhythmia Database. IEEE Transactions on Biomedical Engineering, BME-33(12), 1157-1165. doi:10.1109/tbme.1986.325695Besio, W., & Chen, T. (2007). Tripolar Laplacian electrocardiogram and moment of activation isochronal mapping. Physiological Measurement, 28(5), 515-529. doi:10.1088/0967-3334/28/5/006Besio, G., Koka, K., Aakula, R., & Weizhong Dai. (2006). Tri-polar concentric ring electrode development for Laplacian electroencephalography. IEEE Transactions on Biomedical Engineering, 53(5), 926-933. doi:10.1109/tbme.2005.863887Setti, L., Fraleoni-Morgera, A., Ballarin, B., Filippini, A., Frascaro, D., & Piana, C. (2005). An amperometric glucose biosensor prototype fabricated by thermal inkjet printing. Biosensors and Bioelectronics, 20(10), 2019-2026. doi:10.1016/j.bios.2004.09.022Reddy, A. S. G., Narakathu, B. B., Atashbar, M. Z., Rebros, M., Rebrosova, E., & Joyce, M. K. (2011). Gravure Printed Electrochemical Biosensor. Procedia Engineering, 25, 956-959. doi:10.1016/j.proeng.2011.12.235Gruetzmann, A., Hansen, S., & Müller, J. (2007). Novel dry electrodes for ECG monitoring. Physiological Measurement, 28(11), 1375-1390. doi:10.1088/0967-3334/28/11/005LI, G., LIAN, J., SALLA, P., CHENG, J., RAMACHANDRA, I., SHAH, P., … HE, B. (2003). Body Surface Laplacian Electrocardiogram of Ventricular Depolarization in Normal Human Subjects. Journal of Cardiovascular Electrophysiology, 14(1), 16-27. doi:10.1046/j.1540-8167.2003.02199.

Lepton Flavour Violating Leptonic/Semileptonic Decays of Charged Leptons in the Minimal Supersymmetric Standard Model

We consider the leptonic and semileptonic (SL) lepton flavour violating (LFV) decays of the charged leptons in the minimal supersymmetric standard model (MSSM). The formalism for evaluation of branching fractions for the SL LFV charged-lepton decays with one or two pseudoscalar mesons, or one vector meson in the final state, is given. Previous amplitudes for the SL LFV charged-lepton decays in MSSM are improved, for instance the $\gamma$-penguin amplitude is corrected to assure the gauge invariance. The decays are studied not only in the model-independent formulation of the theory in the frame of MSSM, but also within the frame of the minimal supersymmetric SO(10) model within which the parameters of the MSSM are determined. The latter model gives predictions for the neutrino-Dirac Yukawa coupling matrix, once free parameters in the model are appropriately fixed to accommodate the recent neutrino oscillation data. Using this unambiguous neutrino-Dirac Yukawa couplings, we calculate the LFV leptonic and SL decay processes assuming the minimal supergravity scenario. A very detailed numerical analysis is done to constrain the MSSM parameters. Numerical results for SL LFV processes are given, for instance for tau -> e (mu) pi0, tau -> e (mu) eta, tau -> e (mu) eta', tau -> e (mu) rho0, tau -> e (mu) phi, tau -> e (mu) omega, etc.Comment: 36 pages, 3 tables, 5 .eps figure

Search for Chargino-Neutralino Associated Production at the Fermilab Tevatron Collider

We have searched in $p \bar{p}$ collisions at $\sqrt{s}$ = 1.8 TeV for events with three charged leptons and missing transverse energy. In the Minimal Supersymmetric Standard Model, we expect trilepton events from chargino-neutralino (\chione \chitwo) pair production, with subsequent decay into leptons. We observe no candidate $e^+e^-e^\pm$, $e^+e^-\mu^\pm$, $e^\pm\mu^+\mu^-$ or $\mu^+\mu^-\mu^\pm$ events in 106 pb$^{-1}$ integrated luminosity. We present limits on the sum of the branching ratios times cross section for the four channels: \sigma_{\chione\chitwo}\cdot BR(\chione\chitwo\to 3\ell+X) 81.5 \mgev\sp and M_\chitwo > 82.2 \mgev\sp for $\tan\beta=2$, $\mu =-600$~\mgev\sp and M_\squark= M_\gluino.Comment: 9 pages and 3 figure

Clinical factors associated with a Candida albicans Germ Tube Antibody positive test in Intensive Care Unit patients

Background: Poor outcomes of invasive candidiasis (IC) are associated with the difficulty in establishing the microbiological diagnosis at an early stage. New scores and laboratory tests have been developed in order to make an early therapeutic intervention in an attempt to reduce the high mortality associated with invasive fungal infections. Candida albicans IFA IgG has been recently commercialized for germ tube antibody detection (CAGTA). This test provides a rapid and simple diagnosis of IC (84.4% sensitivity and 94.7% specificity). The aim of this study is to identify the patients who could be benefited by the use of CAGTA test in critical care setting. Methods: A prospective, cohort, observational multicentre study was carried out in six medical/surgical Intensive care units (ICU) of tertiary-care Spanish hospitals. Candida albicans Germ Tube Antibody test was performed twice a week if predetermined risk factors were present, and serologically demonstrated candidiasis was considered if the testing serum dilution was >= 1: 160 in at least one sample and no other microbiological evidence of invasive candidiasis was found. Results: Fifty-three critically ill non-neutropenic patients (37.7% post surgery) were included. Twenty-two patients (41.5%) had CAGTA-positive results, none of them with positive blood culture for Candida. Neither corrected colonization index nor antifungal treatment had influence on CAGTA results. This finding could corroborate that the CAGTA may be an important biomarker to distinguish between colonization and infection in these patients. The presence of acute renal failure at the beginning of the study was more frequent in CAGTA-negative patients. Previous surgery was statistically more frequent in CAGTA-positive patients. Conclusions: This study identified previous surgery as the principal clinical factor associated with CAGTA-positive results and emphasises the utility of this promising technique, which was not influenced by high Candida colonization or antifungal treatment. Our results suggest that detection of CAGTA may be important for the diagnosis of invasive candidiasis in surgical patients admitted in ICU.This study has been supported by a Pfizer research gran

Disk-mediated accretion burst in a high-mass young stellar object

Solar-mass stars form via disk-mediated accretion. Recent findings indicate that this process is probably episodic in the form of accretion bursts1, possibly caused by disk fragmentation2, 3, 4. Although it cannot be ruled out that high-mass young stellar objects arise from the coalescence of their low-mass brethren5, the latest results suggest that they more likely form via disks6, 7, 8, 9. It follows that disk-mediated accretion bursts should occur10, 11. Here we report on the discovery of the first disk-mediated accretion burst from a roughly twenty-solar-mass high-mass young stellar object12. Our near-infrared images show the brightening of the central source and its outflow cavities. Near-infrared spectroscopy reveals emission lines typical for accretion bursts in low-mass protostars, but orders of magnitude more luminous. Moreover, the released energy and the inferred mass-accretion rate are also orders of magnitude larger. Our results identify disk-accretion as the common mechanism of star formation across the entire stellar mass spectrum

Relationship between olive oil consumption and ankle-brachial pressure index in a population at high cardiovascular risk

The aim of this study was to ascertain the association between the consumption of different categories of edible olive oils (virgin olive oils and olive oil) and olive pomace oil and ankle-brachial pressure index (ABI) in participants in the PREDIMED-Plus study, a trial of lifestyle modification for weight and cardiovascular event reduction in individuals with overweight/obesity harboring the metabolic syndrome. Methods: We performed a cross-sectional analysis of the PREDIMED-Plus trial. Consumption of any category of olive oil and olive pomace oil was assessed through a validated food-frequency questionnaire. Multivariable linear regression models were fitted to assess associations between olive oil consumption and ABI. Additionally, ABI ≤1 was considered as the outcome in logistic models with different categories of olive oil and olive pomace oil as exposure. Results: Among 4330 participants, the highest quintile of total olive oil consumption (sum of all categories of olive oil and olive pomace oil) was associated with higher mean values of ABI (beta coefficient: 0.014, 95% confidence interval [CI]: 0.002, 0.027) (p for trend = 0.010). Logistic models comparing the consumption of different categories of olive oils, olive pomace oil and ABI ≤1 values revealed an inverse association between virgin olive oils consumption and the likelihood of a low ABI (odds ratio [OR] 0.73, 95% CI [0.56, 0.97]), while consumption of olive pomace oil was positively associated with a low ABI (OR 1.22 95% CI [1.00, 1.48]). Conclusions: In a Mediterranean population at high cardiovascular risk, total olive oil consumption was associated with a higher mean ABI. These results suggest that olive oil consumption may be beneficial for peripheral artery disease prevention, but longitudinal studies are needed

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Search for gluinos in events with an isolated lepton, jets and missing transverse momentum at √s=13 TeV with the ATLAS detector

The results of a search for gluinos in final states with an isolated electron or muon, multiple jets and large missing transverse momentum using proton–proton collision data at a centre-of-mass energy of √s=13 TeV are presented. The dataset used was recorded in 2015 by the ATLAS experiment at the Large Hadron Collider and corresponds to an integrated luminosity of 3.2 fb−1. Six signal selections are defined that best exploit the signal characteristics. The data agree with the Standard Model background expectation in all six signal selections, and the largest deviation is a 2.1 standard deviation excess. The results are interpreted in a simplified model where pair-produced gluinos decay via the lightest chargino to the lightest neutralino. In this model, gluinos are excluded up to masses of approximately 1.6 TeV depending on the mass spectrum of the simplified model, thus surpassing the limits of previous searches

Lancet

BACKGROUND: In 2015, the second cycle of the CONCORD programme established global surveillance of cancer survival as a metric of the effectiveness of health systems and to inform global policy on cancer control. CONCORD-3 updates the worldwide surveillance of cancer survival to 2014. METHODS: CONCORD-3 includes individual records for 37.5 million patients diagnosed with cancer during the 15-year period 2000-14. Data were provided by 322 population-based cancer registries in 71 countries and territories, 47 of which provided data with 100% population coverage. The study includes 18 cancers or groups of cancers: oesophagus, stomach, colon, rectum, liver, pancreas, lung, breast (women), cervix, ovary, prostate, and melanoma of the skin in adults, and brain tumours, leukaemias, and lymphomas in both adults and children. Standardised quality control procedures were applied; errors were rectified by the registry concerned. We estimated 5-year net survival. Estimates were age-standardised with the International Cancer Survival Standard weights. FINDINGS: For most cancers, 5-year net survival remains among the highest in the world in the USA and Canada, in Australia and New Zealand, and in Finland, Iceland, Norway, and Sweden. For many cancers, Denmark is closing the survival gap with the other Nordic countries. Survival trends are generally increasing, even for some of the more lethal cancers: in some countries, survival has increased by up to 5% for cancers of the liver, pancreas, and lung. For women diagnosed during 2010-14, 5-year survival for breast cancer is now 89.5% in Australia and 90.2% in the USA, but international differences remain very wide, with levels as low as 66.1% in India. For gastrointestinal cancers, the highest levels of 5-year survival are seen in southeast Asia: in South Korea for cancers of the stomach (68.9%), colon (71.8%), and rectum (71.1%); in Japan for oesophageal cancer (36.0%); and in Taiwan for liver cancer (27.9%). By contrast, in the same world region, survival is generally lower than elsewhere for melanoma of the skin (59.9% in South Korea, 52.1% in Taiwan, and 49.6% in China), and for both lymphoid malignancies (52.5%, 50.5%, and 38.3%) and myeloid malignancies (45.9%, 33.4%, and 24.8%). For children diagnosed during 2010-14, 5-year survival for acute lymphoblastic leukaemia ranged from 49.8% in Ecuador to 95.2% in Finland. 5-year survival from brain tumours in children is higher than for adults but the global range is very wide (from 28.9% in Brazil to nearly 80% in Sweden and Denmark). INTERPRETATION: The CONCORD programme enables timely comparisons of the overall effectiveness of health systems in providing care for 18 cancers that collectively represent 75% of all cancers diagnosed worldwide every year. It contributes to the evidence base for global policy on cancer control. Since 2017, the Organisation for Economic Co-operation and Development has used findings from the CONCORD programme as the official benchmark of cancer survival, among their indicators of the quality of health care in 48 countries worldwide. Governments must recognise population-based cancer registries as key policy tools that can be used to evaluate both the impact of cancer prevention strategies and the effectiveness of health systems for all patients diagnosed with cancer. FUNDING: American Cancer Society; Centers for Disease Control and Prevention; Swiss Re; Swiss Cancer Research foundation; Swiss Cancer League; Institut National du Cancer; La Ligue Contre le Cancer; Rossy Family Foundation; US National Cancer Institute; and the Susan G Komen Foundation

Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2)

BACKGROUND: Worldwide data for cancer survival are scarce. We aimed to initiate worldwide surveillance of cancer survival by central analysis of population-based registry data, as a metric of the effectiveness of health systems, and to inform global policy on cancer control. METHODS: Individual tumour records were submitted by 279 population-based cancer registries in 67 countries for 25·7 million adults (age 15-99 years) and 75,000 children (age 0-14 years) diagnosed with cancer during 1995-2009 and followed up to Dec 31, 2009, or later. We looked at cancers of the stomach, colon, rectum, liver, lung, breast (women), cervix, ovary, and prostate in adults, and adult and childhood leukaemia. Standardised quality control procedures were applied; errors were corrected by the registry concerned. We estimated 5-year net survival, adjusted for background mortality in every country or region by age (single year), sex, and calendar year, and by race or ethnic origin in some countries. Estimates were age-standardised with the International Cancer Survival Standard weights. FINDINGS: 5-year survival from colon, rectal, and breast cancers has increased steadily in most developed countries. For patients diagnosed during 2005-09, survival for colon and rectal cancer reached 60% or more in 22 countries around the world; for breast cancer, 5-year survival rose to 85% or higher in 17 countries worldwide. Liver and lung cancer remain lethal in all nations: for both cancers, 5-year survival is below 20% everywhere in Europe, in the range 15-19% in North America, and as low as 7-9% in Mongolia and Thailand. Striking rises in 5-year survival from prostate cancer have occurred in many countries: survival rose by 10-20% between 1995-99 and 2005-09 in 22 countries in South America, Asia, and Europe, but survival still varies widely around the world, from less than 60% in Bulgaria and Thailand to 95% or more in Brazil, Puerto Rico, and the USA. For cervical cancer, national estimates of 5-year survival range from less than 50% to more than 70%; regional variations are much wider, and improvements between 1995-99 and 2005-09 have generally been slight. For women diagnosed with ovarian cancer in 2005-09, 5-year survival was 40% or higher only in Ecuador, the USA, and 17 countries in Asia and Europe. 5-year survival for stomach cancer in 2005-09 was high (54-58%) in Japan and South Korea, compared with less than 40% in other countries. By contrast, 5-year survival from adult leukaemia in Japan and South Korea (18-23%) is lower than in most other countries. 5-year survival from childhood acute lymphoblastic leukaemia is less than 60% in several countries, but as high as 90% in Canada and four European countries, which suggests major deficiencies in the management of a largely curable disease. INTERPRETATION: International comparison of survival trends reveals very wide differences that are likely to be attributable to differences in access to early diagnosis and optimum treatment. Continuous worldwide surveillance of cancer survival should become an indispensable source of information for cancer patients and researchers and a stimulus for politicians to improve health policy and health-care systems